Metraipolis › archive › dc_7ffefd78347e

Use of rituximab for fulminant and refractory cases of immune checkpoint inhibitor induced myocyte injury clinically presenting with features of myasthenia… — Europe PMC PMID:41368047

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41368047
DOI: 10.1093/ehjcr/ytaf593
License (as archived): solo-consultazione
Archived: 2026-11-08T12:02:05.303Z
SHA-256 of the archived text: 77703860fb775f6bcc3355ed576c6553b510816f5bb0d060199d98f2e57db29b
Stable URL of this page: https://metraipolis.com/documento/dc_7ffefd78347e

How to cite

Use of rituximab for fulminant and refractory cases of immune checkpoint inhibitor induced myocyte injury clinically presenting with features of myasthenia… — Europe PMC PMID:41368047 — Europe PMC (en), https://europepmc.org/article/MED/41368047 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7ffefd78347e (Metraipolis archive dc_7ffefd78347e, sha256 77703860fb775f6bcc3355ed576c6553b510816f5bb0d060199d98f2e57db29b)

BibTeX

@misc{dc7ffefd78347e,
  title = {Use of rituximab for fulminant and refractory cases of immune checkpoint inhibitor induced myocyte injury clinically presenting with features of myasthenia… — Europe PMC PMID:41368047},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41368047},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7ffefd78347e; sha256 77703860fb775f6bcc3355ed576c6553b510816f5bb0d060199d98f2e57db29b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41368047. Agents can read the archived copy with the MCP tool read_document.